Category Archives: Cancer Treatment

Why Oncotarget is the Best Source of News on Oncology and Related Medical Fields

Finding articles and the latest news in the field of Medicine online can be quite tricky. This is because one is required to be a researcher with a university before accessing various articles. Open access news channels like Oncotarget enable you to keep tabs with the latest news. Oncotarget is a free access journal that features articles covering multiple disciplines. They began publishing in 2010. Impact Journals publishes Oncotarget. It is indexed and abstracted by PubMed, MEDLINE, Index Medicus and Scopus among others. The editors of the journal are Mikhail Blagosklonny and Andrei Gudkov. Oncology forms the primary content of articles in Oncotarget. The impact that the medical journal has had in the fight against cancer has prompted them to start covering other fields of Medicine like Neuroscience, Cell Biology, Pharmacology, Cardiology, Immunology and the concept of aging among many different areas.Breaking the research barriers between different fields of medicine.

According to Oncotarget, is the sole way to share breakthroughs and discoveries in various areas. Its popularity has mainly risen because of helpful and insightful peer-reviews. These reviews make the journal trustworthy and consequently, there is an intensification of the impact of research. The journal has made scientific results widely available due to its open access nature.There are plans to increase the release rate to two times a week from once because of the rising significance of the journal. Journal Citation Reports have placed Oncotarget’s impact factor in 2016 at 5.168.

This value puts them at third place behind e-Life and Oncogene only. On the other hand, ResearchGate sets Oncotarget’s 2016 impact value at 3.45, a value they arrived at based on the number of times that different researchers cited articles in the journal. In 2014, ResearchGate estimated the journal’s impact value at 5.30.All volumes of Oncortarget since 2010 are available online, and anyone can access and print an article for research purposes. Once on their website, all you need to do is search for any piece you need, and it will pop on your screen in seconds. You can also get links to these articles from Oncotarget’s social media platforms like Twitter, and Facebook.

Eric Lefkofsky and the Tempus Solution to Cancer Care

Cancer is one of the most terrifying diagnosis that can be handed down to a patient sitting within their doctors office. Medical research is an industry unto itself and bright minds around the world are focused on finding a way to make that diagnosis just a little less intimidating. Eric Lefkofsky is one of the brighter tech minds coming out of Chicago in recent decades. He’s established himself as someone who can innovate within the specialty niche of data focused precision medicine. This specialty brought Lefkofsky to found his latest company, Tempus.

The healthcare industry is an industry that is always seemingly on the cutting edge of something new — and it’s important that it is. In order for lives to be saved, technological innovations have to be coming through the door at a record pace. A few years back the introduction of Electronic Health Records, otherwise known as EHRs, gave life to the industry. Now, years later, we know that they aren’t enough. Medical records are still notoriously sloppy and hard to corroborate between clinics and nowhere is this more apparent than within the realm of cancer-care. This is the niche that Tempus is diving into and this is the service that Lefkofsky wants to remedy.

Tempus is Eric Lefkofsky’s latest start up and his mission statement is to fundamentally change the way that cancer care and cancer research is approached. Tempus is an analytical piece of software that looks at a patient’s molecular and clinical data before streamlining the process into a digital interface. This data is primarily focused on genomic information. This data is then accessible by cancer care clinics and hospitals all around the country, at least those that interface with the Tempus system. Lefkofsky’s plan was to introduce a new operating system, sort of like a digital blanket, that lay directly over top the already implemented EHRs.

Lefkofsky is focused on the development of genome sequencing because he believes it to be the key to unlock cancer research. Lefkofsky believes, and medical research backs him up, that the human gene has the information required to find more effective paths to treatment for cancer.

To know more visit @: lefkofskyfoundation.com/about-eric-lefkofsky/

[Top]

Erik Lefkofsky sees the coming genomic revolution as a watershed moment in medicine

Eric Lefkofksy is a giant of the tech startup world. After having co-founded Groupon, a highly innovative firm that uses the power of volume purchasing to extend deep discounts to buyers, who are located all across the world, Lefkofsky has gone on to create a half-dozen other startups that have proven him as one of the top entrepreneurs in the country.

But in 2013, Lefkofsky’s wife received terrible news. She had been diagnosed with an advanced case of breast cancer and would need to begin aggressive treatment immediately. As shocked as Lefkofsky was at his wife’s sudden plight, he was even more taken aback by the apparently lackadaisical approach that the entire oncology profession apparently took towards the collation utilization of data. Lefkofksy noted that many of the oncologists, who were helping his wife fight to stay alive, had lower quality data to work with than many of the country’s truck drivers.

Fortunately, Lefkofsky’s wife made it through the ordeal fine and, today, is a cancer survivor. But one other good thing came from the Lefkofsky family’s cancer travails. In 2016, Eric Lefkofsky founded Tempus, an organization dedicated to bringing state-of-the-art data collection and analysis techniques to oncologists across the country.

Tempus uses many sources of data. These range from electronic medical records to high-level meta-studies of large research cohorts and everything in between. However, the most daunting source of new data for the company’s software solutions is the human genome itself. Today, it is not just possible but economically viable to sequence virtually anyone’s genome. This is a recent development and one that Lefkofsky says will only become cheaper and easier in the coming years.

With the vast trove of data that knowing full patient genomes can bring, Lefkofsky says that oncologists will be able to attain a level of granularity in their understanding of both cancer types treatment responses that has never before even been imagines.

They will be able to break patient cohorts into nearly infinite subgroups, tailor-making treatment regimens that are most likely to succeed for the individual patient, not a crudely defined group of 100,000 people.

Learn More: chicagoinno.streetwise.co/2016/07/22/eric-lefkofskys-next-move-curing-cancer-at-tempus/

[Top]